Therapeutic area intelligence for High-Grade Glioma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Dabrafenib →

olutasidenib →

Recent signals(2)

ClinicalJuly 31, 2026

Efficacy Study of Olutasidenib and Temozolomide in IDH1-Mutant High-Grade Glioma

A study is underway to evaluate the efficacy of olutasidenib combined with temozolomide in treating IDH1-mutant high-grade glioma in pediatric and young adult patients.

ClinicalJuly 12, 2026

Phase II Trial of Dabrafenib and Trametinib in BRAF V600-Mutant High-Grade Glioma

A phase II trial is investigating the efficacy of dabrafenib and trametinib following radiation therapy in patients with BRAF V600-mutant high-grade glioma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.